Sarah K. McGill

Sarah K. McGill

Auto-generated profile, based on publicly available information

Sarah K. McGill

University of North Carolina at Chapel Hill

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2021 in Medical Image Analysis
Verified
Journal Article
Closed access
RMRuibin Ma
Ruibin Ma
RWRui Wang
Rui Wang
YZYubo Zhang
Yubo Zhang
SPStephen Pizer
Stephen Pizer
SMSarah K. McGill
Sarah K. McGill
JFJan-Michael Frahm
Jan-Michael Frahm

24 February 2023 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
SMSarah K. McGill
Sarah K. McGill
JHJana G. Hashash
Jana G. Hashash
TPThomas A. Platts-Mills
Thomas A. Platts-Mills

29 January 2021 in Gastroenterology
Verified
Journal Article
Open access
MCMichael P. Croglio
Michael P. Croglio
SCScott P. Commins
Scott P. Commins
SMSarah K. McGill
Sarah K. McGill

16 February 2023 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
SMSarah K. McGill
Sarah K. McGill
SCScott P. Commins
Scott P. Commins
APAnne F. Peery
Anne F. Peery
JGJoseph Galanko
Joseph Galanko
TKTemitope O. Keku
Temitope O. Keku
RSRobert S. Sandler
Robert S. Sandler
INTRODUCTION: Patients with alpha-gal syndrome, a delayed reaction to mammalian meat, can present with isolated gastrointestinal (GI) symptoms. We aimed to estimate the frequency of alpha-gal sensitization in a Southeastern US population and determine the association between sensitization and mammalian product dietary intake or GI symptoms. METHODS: We performed a cross-sectional study of participants who underwent a screening colonoscopy at our center between 2013 and 2015. We quantified serum alpha-gal immunoglobulin E antibodies in participants who were prospectively enrolled at screening colonoscopy and compared diet intake and lower GI symptoms reported in standardized questionnaires among those with elevated versus no alpha-gal IgE antibodies. RESULTS: Alpha-gal IgE antibodies were common—31.4% of screening colonoscopy participants (127 of 404) had elevated serum alpha-gal IgE >0.1 kU/L. Alpha-gal–sensitized participants endorsed similar rates of abdominal pain compared with those without alpha-gal antibodies (33% vs 38%, adjusted odds ratio 0.9, 95% confidence interval 0.7–1.3). Mammalian meat consumption did not differ based on alpha-gal sensitization status (average 1.43 servings/d in sensitized subjects vs 1.50 in alpha-gal IgE–negative subjects, P = 0.9). Alpha-gal–sensitized participants with levels ≥10 (n = 21) were overrepresented in the lowest quartiles of mammalian meat consumption, but not among those with GI symptoms in general. Participants with high alpha-gal antibody levels >2 kU/L (n = 45) or ≥10 U/L (n = 21) did not have a reduced mean daily mammalian meat intake compared with seronegative people. DISCUSSION: Elevated alpha-gal IgE antibodies were common and not associated with a reduced mammalian meat intake, abdominal pain, or diarrhea. Seropositivity did not predict symptomatic alpha-gal sensitization in this general screening population. Other host factors likely contribute to the phenotypic expression of alpha-gal syndrome.

4 February 2021 in Endoscopy
Verified
Journal Article
Closed access
PDF file
SMSarah K. McGill
Sarah K. McGill
JRJulian Rosenman
Julian Rosenman
RWRui Wang
Rui Wang
RMRuibin Ma
Ruibin Ma
JFJan-Michael Frahm
Jan-Michael Frahm
SPStephen Pizer
Stephen Pizer
Some mucosal surfaces on folds and within haustra may not be visualized at all during colonoscopy, and thus precancerous lesions are missed. We describe here preliminary results of an artificial intelligence (AI) technology that identifies and quantifies these “blind spots,” with the aim, potentially, that endoscopists may be directed to them in real time. Anonymized colonoscopy videos were acquired from a single endoscopist with a high (47 %) adenoma detection rate (ADR), using Olympus CF and PCF devices (Olympus USA, Valley Forge, Pennsylvania, USA) and high definition recording (Epiphan, Palo Alto, California, USA). The main AI modalities applied were a recurrent neural network (an AI type particularly suitable for sequential data), that had been trained to compute depth [1] [2] combined with visual simultaneous localization and mapping (SLAM) [3]. The AI software was applied to 76 colonoscopy video sequences from 18 patients, showing colon segments of 4–25 cm in length. This created three-dimensional (3 D) reconstructions of the colon segments and then identified blind spots, showing as holes or gaps in the reconstructions, and quantified these nonvisualized areas. The study endoscopist reviewed the reconstructions and validated that the blind spots had not been seen in the colonoscopy video. The last 12 3 D reconstructions were done in real time with the video sequence; these were 2–6 seconds in duration, corresponding to colon lengths of 7–25 cm (median 10 cm). [Video 1] shows a colonoscopy video alongside the real-time reconstruction highlighting a blind spot. [Fig. 1] is an example of a reconstructed segment of colon with no blind spot, while [Fig. 2] shows a sequence of video images where the left wall of the colon was not visualized because of the camera angle, and the reconstructions with corresponding gaps. Video 1 Artificial-intelligence identification and quantification of colonoscopy blind spots. The video shows the colonoscopy video (left) and real-time reconstruction (center and right) which highlights the blind spot in the colon wall. Our system calculated that among the 76 reconstructed segments, the blind spots ranged from 1 % to 50 % of the total surface area (interquartile range 8.7 %–27 %), with a median 19 % of surface area being missed despite the high ADR of the operator. [Fig. 3] shows the distribution of the differing missed area percentages among the 76 reconstructed colonic segments. Endoscopy_UCTN_Code_TTT_1AQ_2AB Article published online: 04 February 2021 © 2021. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

2 January 2023 in Journal of Clinical Gastroenterology
Verified
Journal Article
Closed access
SMSarah K. MD McGill
Sarah K. MD McGill
MLMichael E. Mbbs Levin
Michael E. Mbbs Levin
NSNicholas J. Shaheen
Nicholas J. Shaheen
CCCary C. Cotton
Cary C. Cotton
TPThomas A. Platts-Mills
Thomas A. Platts-Mills
SCScott P. Commins
Scott P. Commins
Background and Aims: Alpha-gal allergy causes a delayed reaction to mammalian meats and has been reported worldwide. Patients with the allergy may present with isolated gastrointestinal (GI) symptoms, but this phenotype is poorly understood. Methods: We pooled and analyzed symptoms and demographics of patients from two prospective cohorts of patients with a diagnosis of alpha-gal allergy who reacted after eating mammalian meat under observation. We compared the characteristics of patients who demonstrated GI-isolated symptoms on a challenge with those who exhibited symptoms outside the GI tract (skin, respiratory, and circulatory). Results: Among the 91 children and adult alpha-gal allergic patients who exhibited symptoms after oral challenge with mammalian meat, 72.5% experienced GI distress with one or more GI symptoms, which was the most frequent class of symptoms, compared with skin changes in 57.1% and respiratory distress in 5.5%. The most common GI symptoms were abdominal pain (71%) and vomiting (22.0%). GI-isolated symptoms occurred in 37 patients (40.7%) who reacted, and those patients reacted more quickly than patients who exhibited systemic symptoms (median onset of symptoms in GI-isolated group 90 min vs 120 min) and were more likely to be children than adults (relative risk=1.94, 95% CI: 1.04-3.63). Conclusions: Isolated-GI distress occurred in 4 in every 10 alpha-gal allergic individuals who developed symptoms on oral food challenge with mammalian meat. Alpha-gal allergic patients, particularly children, may exhibit GI distress alone, and adult and pediatric gastroenterologists should be aware of the diagnosis and management of the allergy.